Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics develops investigational therapies for liver and viral diseases as a clinical-stage biotechnology company. Its news centers on programs for chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis, obesity, and coronavirus infections, including pevifoscorvir sodium, ALG-055009, ALG-097558, and ALG-170675.
Recurring updates cover clinical and nonclinical data, regulatory designations, scientific-conference presentations, quarterly financial results, research and development spending, licensing agreements, and equity compensation actions. Company releases also describe the Phase 2 B-SUPREME study of pevifoscorvir sodium, FDA Fast Track Designation for chronic HBV infection, and the exclusive license agreement for Greater China with Xiamen Amoytop Biotech.
Aligos Therapeutics (Nasdaq: ALGS) announced a collaboration with Merck to leverage its oligonucleotide platform technology for developing therapies targeting non-alcoholic steatohepatitis (NASH) and potentially other conditions. The agreement includes an upfront payment and up to $458M in development milestones along with tiered royalties on sales. Aligos will focus on designing and optimizing oligonucleotides, while Merck will handle clinical development and commercialization. This collaboration aims to address the critical need for effective NASH treatments amidst growing liver disease concerns.
Aligos Therapeutics (Nasdaq: ALGS) presented six posters and one oral presentation at the AASLD Liver Meeting Digital Experience 2020, highlighting advancements in its liver disease programs. Key updates included progress on chronic hepatitis B (CHB) therapies and the nonalcoholic steatohepatitis (NASH) treatment candidate ALG-055009. The company is optimistic about its combination regimens for CHB that may lead to functional cures and has begun Phase 1 trials for two drug candidates, ALG-010133 and ALG-000184, aimed at CHB.
Aligos Therapeutics (Nasdaq: ALGS) announced participation in two virtual investor conferences: the Jefferies 2020 Virtual London Healthcare Conference from November 17-19, and the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3. Management will present at both events and will be available for one-on-one meetings. Aligos focuses on developing novel therapeutics for viral infections and liver diseases, aiming to advance targeted antiviral therapies.
Aligos Therapeutics (Nasdaq: ALGS) has announced that its Belgian subsidiary, Aligos Belgium BV, received a €1.8M grant from the Flemish Agency for Innovation and Entrepreneurship (VLAIO) to support a nonclinical research project on combination therapy for Chronic Hepatitis B (CHB). This three-year project, named CoHeBA, aims to explore the therapeutic candidates' mechanisms and involves collaborations with leading laboratories globally. Aligos CEO Lawrence Blatt expressed optimism that project outcomes will enhance their therapeutic developments for CHB, which affects over 290 million people worldwide.
Aligos Therapeutics (Nasdaq: ALGS) announced the dosing of its first subject in the Phase 1a/b trial of ALG-000184, a novel treatment targeting hepatitis B virus (HBV). This trial aims to assess the safety, pharmacokinetics, and antiviral activity of ALG-000184 in patients with chronic hepatitis B. The company anticipates sharing initial topline results in the second half of 2021. The trial marks the second drug candidate from Aligos’s CHB portfolio to enter clinical studies this year, affirming their commitment to developing innovative therapies for unmet medical needs in liver diseases.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) has priced its initial public offering of 10 million shares at $15.00 each, aiming for gross proceeds of approximately $150 million. The underwriters have a 30-day option for an additional 1.5 million shares. The common stock will commence trading on Nasdaq on October 16, 2020, with the offering expected to close on October 20, 2020, pending customary conditions. J.P. Morgan, Jefferies, and Piper Sandler are managing the offering.